Cargando…
Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect
Recently, bisphosphonates (BPs) have been widely used in medical practice as anti-resorptive agents owing to their anti-osteoclatic action. In addition, these compounds are also used for their analgesic action and their potential anti-tumour effect. Patients treated with BPs may subsequently develop...
Autores principales: | Sharma, Dileep, Ivanovski, Saso, Slevin, Mark, Hamlet, Stephen, Pop, Tudor S, Brinzaniuc, Klara, Petcu, Eugen B, Miroiu, Rodica I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606312/ https://www.ncbi.nlm.nih.gov/pubmed/23316704 http://dx.doi.org/10.1186/2045-824X-5-1 |
Ejemplares similares
-
Bisphosphonate-related osteonecrosis of jaw (BRONJ): an anti-angiogenic side-effect?
por: Petcu, Eugen B, et al.
Publicado: (2012) -
Bisphosphonate-related osteonecrosis of the jaws (Bronj)
por: Beninati, Francesco, et al.
Publicado: (2013) -
Bisphosphonate related osteonecrosis of the jaws (BRONJ) in osteoporotic males
por: Kwon, Yong-Dae, et al.
Publicado: (2016) -
Local delivery of hydrogel encapsulated vascular endothelial growth factor for the prevention of medication-related osteonecrosis of the jaw
por: Sharma, Dileep, et al.
Publicado: (2021) -
Development of animal model for Bisphosphonates-related osteonecrosis of the jaw (BRONJ)
por: Jang, Hyo-Won, et al.
Publicado: (2015)